Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Dyax resuming DX-88 trials

DYAX said FDA released the clinical hold on DX-88, allowing the company to

Read the full 131 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE